PORTFOLIO

PORTFOLIO COMPANIES

Metcela Inc.

  • Co-CEO:
    Kenichi Nogami
  • Co-CEO:
    Takahiro Iwamiya, PhD.

URL:https://www.metcela.com/en/

COMPANY PROFILE

Revolutionizing the Way We Treat Heart Failure

Founded in 2016, Metcela is a clinical stage biotech company, researching and developing regenerative cell therapies. Based on Dr. Iwamiya’s research on a type of fibroblastcalled VCAM-1-positive Cardiac Fibroblasts (VCF), the company is now working on the application of an autologous & tissue-specific cell therapy for ischemic heart failure. The First-in-Human Phase I clinical trial will be initiated in 2021.

COMPANY STORY

Origin

Mr. Nogami and Dr. Iwamiya founded Metcela in 2016 to commercialize Dr. Iwamiya’s academic research findings at Tokyo Women’s Medical University

Strength

・Autologous and tissue-specific cell therapy: high efficacy and low-cost manufacturing
・Unique positioning by combining the cells with a proprietary mapping and catheter delivery technology which enables safe and accurate cell injections to the heart
・Proven mechanism of action of the therapy as a platform-enabling technology, in addition to proven efficacy in multiple animal models


UTEC’s value add

Financial strategy and hiring talents
  • Human VCAM-1-positive Cardiac Fibroblasts

  • Cardiomyocytes and VCFs forms a tight network when co-cultured together

  • 4 clear pillars distinguishing Metcela from the rest